{"id":"enfortumab-vedotin-ejfv","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"31%","effect":"Nausea"},{"rate":"28%","effect":"Diarrhea"},{"rate":"25%","effect":"Abdominal pain"},{"rate":"24%","effect":"Muscle spasms"},{"rate":"22%","effect":"Weight loss"},{"rate":"21%","effect":"Vomiting"},{"rate":"20%","effect":"Dysgeusia"},{"rate":"19%","effect":"Mucosal inflammation"},{"rate":"18%","effect":"Thirst"}]},"_chembl":{"chemblId":"CHEMBL3301589","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to Nectin-4 on the surface of cancer cells, which leads to the internalization and degradation of the cells. This results in the inhibition of tumor growth and the induction of apoptosis.","oneSentence":"Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:50:50.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic urothelial cancer"},{"name":"Locally advanced or metastatic urothelial cancer with disease progression during or following platinum-containing chemotherapy, or within 12 months of receiving previous adjuvant chemotherapy in the neoadjuvant or adjuvant setting"}]},"trialDetails":[{"nctId":"NCT04963153","phase":"PHASE1","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-07","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":24},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT06764095","phase":"PHASE4","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-01-08","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":75},{"nctId":"NCT05775471","phase":"PHASE2","title":"Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-06-26","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":21},{"nctId":"NCT04878029","phase":"PHASE1","title":"Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-07-23","conditions":"Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":32},{"nctId":"NCT06104618","phase":"PHASE2","title":"Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-12-21","conditions":"Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8","enrollment":28},{"nctId":"NCT07087860","phase":"PHASE2","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-01","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":70},{"nctId":"NCT04724018","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan Plus EV in Metastatic UC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-05-20","conditions":"Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter","enrollment":106},{"nctId":"NCT04887870","phase":"PHASE2, PHASE3","title":"Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-29","conditions":"Advanced or Metastatic Solid Malignancies","enrollment":52},{"nctId":"NCT06356155","phase":"PHASE2","title":"Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-22","conditions":"Urothelial Carcinoma","enrollment":32},{"nctId":"NCT05756569","phase":"PHASE2","title":"Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-09-26","conditions":"Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm","enrollment":25}],"_emaApprovals":[],"_faersSignals":[{"count":38,"reaction":"DEATH"},{"count":38,"reaction":"FATIGUE"},{"count":35,"reaction":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION"},{"count":34,"reaction":"RASH"},{"count":33,"reaction":"DIARRHOEA"},{"count":32,"reaction":"NAUSEA"},{"count":32,"reaction":"NEUROPATHY PERIPHERAL"},{"count":31,"reaction":"DECREASED APPETITE"},{"count":24,"reaction":"PRURITUS"},{"count":23,"reaction":"ALOPECIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PADCEV"],"phase":"phase_2","status":"active","brandName":"Enfortumab Vedotin-Ejfv","genericName":"Enfortumab Vedotin-Ejfv","companyName":"Mirati Therapeutics Inc.","companyId":"mirati-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4. Used for Locally advanced or metastatic urothelial cancer, Locally advanced or metastatic urothelial cancer with disease progression during or following platinum-containing chemotherapy, or within 12 months of receiving previous adjuvant chemotherapy in the neoadjuvant or adjuvant setting.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}